Max Robotics — Global Service Robot Directory + US Certification

About

Tanguy Y. Seiwert is a leading oncologist and researcher whose work centers on head and neck cancers, with a particular focus on human papillomavirus-positive oropharyngeal cancer (HPV+ OPC) and the integration of immunotherapy into curative treatment paradigms. His major contributions include pioneering the use of neoadjuvant nivolumab combined with chemotherapy, followed by response-adaptive therapy, to improve outcomes while potentially de-escalating locoregional treatment. This approach, demonstrated in the OPTIMA II trial (2021, 30 citations), has been instrumental in shifting the field toward risk-adapted, de-escalation strategies that reduce treatment toxicity without compromising survival. His 2024 study on neoadjuvant nivolumab plus chemotherapy (45 citations) further solidifies the role of immune checkpoint inhibitors in the curative setting. Seiwert has also highlighted disparities in care, showing that survival outcomes for HPV+ OPC patients are lower at community cancer centers compared to academic centers, underscoring the need for equitable access to advanced surgical and multidisciplinary care. With a strong record of impactful clinical trials and translational research, Seiwert continues to shape the future of personalized, immunotherapy-driven treatment for head and neck cancers.